Perioperative Glucose Monitoring and Treatment to Reduce Risk of Surgical Site Infections and Complications
Launched by ST. PETER'S HOSPITAL, ALBANY, NY · Jan 3, 2025
Trial Information
Current as of November 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study, called Perioperative Glucose Monitoring (POGM), asks whether closely watching and treating blood sugar during surgery lasting 2 hours or more can lower the risk of surgical site infections and other complications in the first 30 days after surgery. Before surgery, researchers will measure a blood test called HbA1c to help decide the insulin plan. During the operation, blood sugar is checked every 2 hours with a quick finger-prick test, and if it rises above 150 mg/dL, a fast-acting insulin (insulin lispro) is given according to a standard sliding-scale plan. Glucose monitoring may continue for up to 48 hours after surgery, aiming to keep blood sugar in a safe range guided by current recommendations. The main outcome they’re looking at is surgical site infections within 30 days; a secondary outcome is other postoperative complications in the same timeframe.
Who can participate: adults age 18 and older undergoing a surgical procedure expected to last at least 2 hours can join, regardless of sex or background. People with Type 1 diabetes or other strict endocrinology orders are not eligible. The study is being conducted at St. Peter’s Hospital in Albany, NY, and is currently enrolling by invitation with about 266 participants planned. If you participate, you’ll have your medical data reviewed for the study, including perioperative glucose readings and 30-day follow-up for infections or other complications. At this time, results from the trial have not yet been published.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Any adult surgical patient who undergoes a procedure expecting to last 2 or more hours regardless of age, gender, race, sex, religion, nation of origin, or other identifiable demographics -
- • Exclusion Criteria: Type 1 Diabetes or other patients with strick endocrinology orders
- • -
About St. Peter's Hospital, Albany, Ny
St. Peter's Hospital, located in Albany, New York, is a leading healthcare institution dedicated to providing high-quality patient care and advancing medical research. As a clinical trial sponsor, the hospital leverages its extensive resources and expertise to facilitate innovative research initiatives aimed at improving health outcomes. With a commitment to patient safety and ethical standards, St. Peter's Hospital collaborates with a diverse team of healthcare professionals and researchers to conduct rigorous clinical trials across various therapeutic areas. This dedication to clinical excellence not only enhances the hospital's clinical offerings but also contributes to the broader medical community's knowledge and practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Albany, New York, United States
Patients applied
Trial Officials
Jamila Benmoussa, MD
Study Director
St. Peter's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported